Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2020 Dec;26(12):1852-1858.
doi: 10.1038/s41591-020-1089-8. Epub 2020 Oct 26.

Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial

Affiliations
Clinical Trial

Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial

Amy Burd et al. Nat Med. 2020 Dec.

Abstract

Acute myeloid leukemia (AML) is the most common diagnosed leukemia. In older adults, AML confers an adverse outcome1,2. AML originates from a dominant mutation, then acquires collaborative transformative mutations leading to myeloid transformation and clinical/biological heterogeneity. Currently, AML treatment is initiated rapidly, precluding the ability to consider the mutational profile of a patient's leukemia for treatment decisions. Untreated patients with AML ≥ 60 years were prospectively enrolled on the ongoing Beat AML trial (ClinicalTrials.gov NCT03013998 ), which aims to provide cytogenetic and mutational data within 7 days (d) from sample receipt and before treatment selection, followed by treatment assignment to a sub-study based on the dominant clone. A total of 487 patients with suspected AML were enrolled; 395 were eligible. Median age was 72 years (range 60-92 years; 38% ≥75 years); 374 patients (94.7%) had genetic and cytogenetic analysis completed within 7 d and were centrally assigned to a Beat AML sub-study; 224 (56.7%) were enrolled on a Beat AML sub-study. The remaining 171 patients elected standard of care (SOC) (103), investigational therapy (28) or palliative care (40); 9 died before treatment assignment. Demographic, laboratory and molecular characteristics were not significantly different between patients on the Beat AML sub-studies and those receiving SOC (induction with cytarabine + daunorubicin (7 + 3 or equivalent) or hypomethylation agent). Thirty-day mortality was less frequent and overall survival was significantly longer for patients enrolled on the Beat AML sub-studies versus those who elected SOC. A precision medicine therapy strategy in AML is feasible within 7 d, allowing patients and physicians to rapidly incorporate genomic data into treatment decisions without increasing early death or adversely impacting overall survival.

PubMed Disclaimer

Figures

Fig. 1 ∣
Fig. 1 ∣. Overview of the Beat AML trial.
a, AML prioritization by genomic or cytogenetic abnormality into groups. b, Patient distribution following enrollment on the Beat AML trial. c, Genomic assignment of eligible patients with AML by prioritization group. The asterisk denotes the hypermethylation group, which is defined by the TET2/WT1 mutations.
Fig. 2 ∣
Fig. 2 ∣. Comutation oncoprint of eligible Beat AML trial patients.
Genes with genomic alterations (short variants and insertions/deletions) are listed in descending order of frequency and each column represents an individual patient. Red indicates that the alteration was present at an allele frequency of ≥30% and blue <30%.
Fig. 3 ∣
Fig. 3 ∣. Overall survival estimates.
a, All eligible patients on the Beat AML trial. b, By treatment received including assigned Beat AML therapy, SOC (standard therapy), palliative care and alternative investigational therapy. Overall survival estimates were calculated with the Kaplan–Meier method and presented with 95% CIs constructed using the complementary log-log transformation. If a value could not be calculated, not evaluated is indicated. The 2 patients who did not consent to a Beat AML sub-study with unknown treatment were combined with the 38 patients who elected palliative care.

Similar articles

Cited by

References

    1. Karjalainen E & Repasky GA Molecular changes during acute myeloid leukemia (AML) evolution and identification of novel treatment strategies through molecular stratification. Prog. Mol. Biol. Transl. Sci 144, 383–436 (2016). - PubMed
    1. Khwaja A et al. Acute myeloid leukaemia. Nat. Rev. Dis. Primers 2, 16010 (2016). - PubMed
    1. Chen J et al. Myelodysplastic syndrome progression to acute myeloid leukemia at the stem cell level. Nat. Med 25, 103–110 (2019). - PMC - PubMed
    1. Desai P et al. Somatic mutations precede acute myeloid leukemia years before diagnosis. Nat. Med 24, 1015–1023 (2018). - PMC - PubMed
    1. Abelson S et al. Prediction of acute myeloid leukaemia risk in healthy individuals. Nature 559, 400–404 (2018). - PMC - PubMed

Publication types

MeSH terms

Associated data